MONET™ Anterior Cervical Interbody Fusion Cage System

K172788 · Ctl Medical Corporation · ODP · Jun 25, 2018 · Orthopedic

Device Facts

• Record ID: K172788
• Device Name: MONET™ Anterior Cervical Interbody Fusion Cage System
• Applicant: Ctl Medical Corporation
• Product Code: ODP · Orthopedic
• Decision Date: Jun 25, 2018
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 888.3080
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

MONET™ Anterior Cervical Interbody Fusion Cage system is indicated for use in skeletally mature patients with degenerative disc disease (DDD) of the cervical spine with accompanying radicular symptoms at one-disc level. DDD is defined as discogenic pain with degeneration of the disc confirmed by patient history and radiographic studies. MONET™ Anterior Cervical Interbody Fusion Cage system is used to facilitate intervertebral body fusion in the cervical spine at the C2 to C7 disc levels using autograft bone. MONET™ Anterior Cervical Interbody Fusion Cage system is to be used with supplemental fixation systems that have been cleared for use in the cervical spine. Patients should have at least six (6) weeks of non-operative treatment with an intervertebral cage.

Device Story

Interbody fusion cage system; maintains cervical intervertebral spacing; facilitates fusion. Implanted surgically in cervical spine (C2-C7). Available in various sizes/configurations for anatomical fit. Used with autograft bone and supplemental fixation systems. Benefits patient by stabilizing vertebral segment to promote fusion in DDD cases.

Clinical Evidence

Bench testing only. Testing performed per ASTM F2077 (static/dynamic axial compression, compression-shear, torsion) and ASTM F2267 (load-induced subsidence). Static push-out testing also conducted. Results demonstrate performance equivalent to predicate devices.

Technological Characteristics

Materials: PEEK with tantalum markers or titanium alloy. Dimensions/configurations vary to accommodate anatomical requirements. Mechanical testing per ASTM F2077 and ASTM F2267.

Indications for Use

Indicated for skeletally mature patients with cervical degenerative disc disease (DDD) and radicular symptoms at one level (C2-C7). Requires autograft bone and supplemental fixation. Patients must have failed at least 6 weeks of non-operative treatment.

Regulatory Classification

Identification

An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.

Special Controls

*Classification.* (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval. (c) *Date premarket approval application (PMA) or notice of product development protocol (PDP) is required.* Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.

Predicate Devices

• MATISSE™ Anterior Cervical Interbody Fusion Cage System (K121569)
• MATISSE™ Anterior Cervical Interbody Fusion Cage System (K162682)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo features the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue text.

June 25, 2018

CTL Medical Corporation % Mr. Michael A. Patz Senior Regulatory/Clinical Consultant ROMIS. Inc. 110 Haverhill Road, Suite 526 Amesbury, Massachusetts 01913

Re: K172788

Trade/Device Name: MONET™ Anterior Cervical Interbody Fusion Cage System Regulation Number: 21 CFR 888.3080 Regulation Name: Intervertebral Body Fusion Device Regulatory Class: Class II Product Code: ODP Dated: May 16, 2018 Received: May 21, 2018

Dear Mr. Patz:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820);

{1}------------------------------------------------

and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely,

Image /page/1/Picture/6 description: The image shows the text "Melissa Hall-S" in a simple, sans-serif font. The text is black and appears to be the main focus of the image. The background is a light color, possibly white or a very light gray, with a faint watermark or design element that is not clearly visible but adds a subtle texture to the background.

For Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

# Indications for Use

510(k) Number (if known) K172788

#### Device Name

MONETTM Anterior Cervical Interbody Fusion Cage System

#### Indications for Use (Describe)

MONET™ Anterior Cervical Interbody Fusion Cage system is indicated for use in skeletally mature patients with degenerative disc disease (DDD) of the cervical spine with accompanying radicular symptoms at one-disc level. DDD is defined as discogenic pain with degeneration of the disc confirmed by patient history and radiographic studies. MONET™ Anterior Cervical Interbody Fusion Cage system is used to facilitate intervertebral body fusion in the cervical spine at the C2 to C7 disc levels using autograft bone. MONET™ Anterior Cervical Interbody Fusion Cage system is to be used with supplemental fixation systems that have been cleared for use in the cervical spine. Patients should have at least six (6) weeks of non-operative treatment with an intervertebral cage.

Type of Use (Select one or both, as applicable)

| <span style="font-size: 10pt;">☑ Prescription Use (Part 21 CFR 801 Subpart D)</span> |
|--------------------------------------------------------------------------------------|
|--------------------------------------------------------------------------------------|

| <span style="font-size: 10pt;">☐ Over-The-Counter Use (21 CFR 801 Subpart C)</span> |
|-------------------------------------------------------------------------------------|
|-------------------------------------------------------------------------------------|

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail]

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

## 510(k) SUMMARY

## CTL Medical Corporation's MONET™ ACIF Cage

| Submitter: | CTL Medical Corporation<br>Tosan Onosode<br>4550 Excel Parkway, Suite 300<br>Addison, TX 75001<br>Phone: [phone]<br>Fax: [phone] |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| Contact Person: | Michael A. Patz<br>RQMIS, Inc.<br>110 Haverhill Road, Suite 526<br>Amesbury, MA 01913<br>Phone: [phone] |
| Date Prepared: | April 16, 2018 |
| Name of Device: | MONET™ Anterior Cervical Interbody Fusion Cage System |
| Common or Usual Name: | Intervertebral Body Fusion Device |
| Classification Name: | Sec 888.3080-Intervertebral Body Fusion Device<br>Product Code: ODP |

## Predicate Device:

Primary Predicate: K121569, MATISSE™ Anterior Cervical Interbody Fusion Cage System

Additional Predicate: K162682, MATISSE™ Anterior Cervical Interbody Fusion Cage System

# Indications for Use:

MONET™ Anterior Cervical Interbody Fusion Cage system is indicated for use in skeletally mature patients with degenerative disc disease (DDD) of the cervical spine with accompanying radicular symptoms at one-disc level. DDD is defined as discogenic pain with degeneration of the disc confirmed by patient history and radiographic studies. MONET™ Anterior Cervical Interbody Fusion Cage system is used to facilitate intervertebral body fusion in the cervical spine at the C2 to C7 disc levels using autograft bone. MONET™ Anterior Cervical Interbody Fusion Cage system is to

{4}------------------------------------------------

be used with supplemental fixation systems that have been cleared for use in the cervical spine. Patients should have at least six (6) weeks of non-operative treatment prior to treatment with an intervertebral cage.

#### Device Description:

The MONET™ Anterior Cervical Interbody Fusion Cage system is intended for use as an Interbody fusion cage device to maintain cervical intervertebral spacing and must be used with supplemental fixation. The devices are available in a variety of different sizes and configurations to accommodate anatomical variation in different vertebral levels and/or patient anatomy. The devices are made of either PEEK with tantalum markers or titanium allov.

## Technological Characteristics:

The MONET™ Anterior Cervical Interbody Fusion Cage System are manufactured from either PEEK with tantalum markers or titanium alloy, which are the identical materials used to manufacture the predicates. All heights, and widths are within range covered by its predicate device.

## Performance Data:

The MONET™ Anterior Cervical Interbody Fusion Cage System was tested per:

- 1. ASTM F2077: Test Methods for Intervertebral Body Fusion Devices. (2014)
- a. Static and Dynamic Axial Compression
- b. Static and Dynamic Compression-Shear
- c. Static and Dynamic Torsion
- 2. ASTM F2267: Standard Test Method for Measuring Load Induced Subsidence of Intervertebral Body Fusion Device Under Static Axial Compression. (2013)
- 3. Static Push-out Test

Results demonstrated that the performance of the subject device was equivalent to the predicate devices.

### Substantial Equivalence:

The MONET™ Anterior Cervical Interbody Fusion Cage System is as safe and effective as the predicate MATISSE™ Anterior Cervical Interbody Fusion Cage System, Titanium and PEEK (K162682 and K121569). The MONET™ Anterior Cervical Interbody Fusion Cage System has the same intended uses and similar indications, technological characteristics, and principles of operation as its predicate device. The minor

{5}------------------------------------------------

technological differences between the MONET™ Anterior Cervical Interbody Fusion Cage System and its predicate device raise no new issues of safety or effectiveness. Thus, the MONET™ Anterior Cervical Interbody Fusion Cage System is substantially equivalent.